A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

Keyphrases

• High Dose 100%
• Prostate Carcinoma 100%
• Hormone Refractory 100%
• Phase II Study 100%
• Weekly Paclitaxel 100%
• Estramustine 100%
• Total Prostate-specific Antigen 60%
• Paclitaxel 60%
• Prostate-specific Antigen Level 40%
• Maximum Tolerated Dose 40%
• Gastrointestinal Diseases 40%
• Prostate-specific Antigen Response 40%
• Anemia 20%
• Edema 20%
• Neutropenia 20%
• Thromboembolism 20%
• Response Rate 20%
• Diarrhea 20%
• 2-cycles 20%
• Nausea 20%
• Hematologic 20%
• Neurotoxicity 20%
• Measurable Disease 20%
• Neuropathy 20%
• Bone Scan 20%
• Intent-to-treat Analysis 20%
• Abdominal Computed Tomography 20%
• Myelotoxicity 20%
• Hair Loss 20%

Medicine and Dentistry

• Drug Megadose 100%
• Prostate Specific Antigen 100%
• Paclitaxel 100%
• Prostate Carcinoma 100%
• Estramustine 100%
• Oral 100%
• Thromboembolism 40%
• Gastrointestinal Distress 40%
• Antigen Response 40%
• Intention-to-Treat Analysis 20%
• Anemia 20%
• Computer Assisted Tomography 20%
• Edema 20%
• Neuropathy 20%
• Neutropenia 20%
• Diarrhea 20%
• Nausea 20%
• Neurotoxicity 20%
• Bone Scintigraphy 20%
• Bone Marrow Toxicity 20%
• Diseases 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Specific Antigen 100%
• Paclitaxel 100%
• Prostate Carcinoma 100%
• Estramustine 100%
• Thromboembolism 40%
• Maximum Tolerated Dose 40%
• Gastrointestinal Symptom 40%
• Anemia 20%
• Edema 20%
• Neutropenia 20%
• Nausea 20%
• Neuropathy 20%
• Neurotoxicity 20%
• Diarrhea 20%
• Hair Loss 20%
• Bone Marrow Toxicity 20%
• Diseases 20%